Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure



Status:Completed
Conditions:Cancer, Cancer, Bladder Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/22/2019
Start Date:June 2, 2015
End Date:February 2019

Use our guide to learn which trials are right for you!

An Open Label, Single Arm, Phase II, Multicenter Study of the Safety and Efficacy of CG0070 Oncolytic Vector Regimen in Patients With Non-Muscle Invasive Bladder Carcinoma Who Have Failed BCG Therapy and Refused Cystectomy

To study the safety and efficacy of CG0070, an oncolytic virus expression GMCSF in high grade
non muscle invasive bladder cancer patients who failed BCG therapy and refused cystectomy.

The plan is to study the safety and efficacy of CG0070 in high-grade NMIBC patients who
failed BCG therapy. Most patients with NMIBCis (Cis, Cis with Ta and/or T1, high grade Ta or
T1 with frequent or uncontrolled recurrences) who have failed BCG intravesical therapy
(standard of care) usually have no other choice but to proceed to cystectomy. Cystectomy is a
surgery associated with major morbidity, mortality and quality of life issues. Morbidity and
long term tedious medical care will be for the rest of the patient's life span. Most patients
at this stage do not show signs of disease progression into the muscle layer or of
metastasis, making surgery a very difficult decision. CG0070, if successful in this trial,
will serve to provide a therapeutic alternative for this patient population in need.

Inclusion Criteria:

1. Patients must have pathologically confirmed non-muscle invasive bladder cancer (NMIBC)
high grade disease (HG), as defined by the 2004 WHO classification system

2. Patients must have no evidence of muscle invasive disease

3. Patients must be able to provide a sufficient biopsy sample to the central pathologist
for histopathologically confirmed, transitional cell (urothelial) carcinoma.
Urothelial tumors with mixed histology (but with <50% variant) are eligible.

4. Patients must have received at least two or more prior courses of intravesical therapy
per recommended schedules. BCG must have been one of the prior therapies administered.

5. Patients can have either failed BCG induction therapy within a six-month period or
have been successfully treated with BCG, but subsequently found to have recurrence.
The first standard course of intravesical BCG therapy must include at least six weekly
treatments (allowable range of instillations per course is 4-9). The second course of
BCG therapy must include at least two weekly treatments.

6. Patients have either Cis or Cis with Ta and/or T1 disease at enrollment or in the
past. For those patients with only Ta or T1 disease at enrollment AND with no history
of Cis, they must have

- disease recurrence either must occur within 12 months of the most recent
intravesical therapy of any kind, OR

- disease recurrence within 18 months of BCG maintenance OR

- disease recurrence within 24 months of BCG induction

- T1 patients need to have evidence of muscle included in their latest biopsy; and
if not a re-TURBT has to be done prior to enrollment

7. 18 years of age or older

8. Radical cystectomy has been declined by the patient in a signed special section of the
informed consent, whereby there is a clear explanation by the investigator to the
subject that a delay of cystectomy may increase his/her chance of disease progression,
the results of which may lead to serious and life threatening consequences.

9. Patients must be able to enter into the study within ten weeks of their most recent
diagnostic procedure, which is usually a diagnostic biopsy, a transurethral resection
of bladder tumor (TURBT) procedure or positive urine cytology.

10. Eastern Cooperative Oncology Group (ECOG) performance status <2.

11. Not pregnant or lactating

12. Patients with child bearing potential must agree to use adequate contraception

13. Agree to study specific informed consent and HIPAA authorization for release of
personal health information

14. Adequate baseline CBC, renal and hepatic function. Parameters described as WBC>3000
cells/mm^3, ANC>1,000 cells/mm^3, hemoglobin>9.5g/dL, and platelet count >100,000
cells/mm^3

- Adequate renal function: serum creatinine <2.5mg/dL

- Bilirubin, AST and ALT not more than 2 x Upper Limits of Normal

- PT/INR, PTT, and fibrinogen within institutional acceptable limits

- Absolute lymphocyte count ≥ 800/μL before the first dose of CG0070

Exclusion Criteria:

1. Previous systemic chemotherapy or radiation for bladder cancer. Note: Prior
immunotherapy or intravesical (administered within the bladder) chemotherapy for
superficial disease is acceptable

2. History of anaphylactic reaction following exposure to humanized or human therapeutic
monoclonal antibodies, hypersensitivity to GM-CSF or yeast derived products,
clinically meaningful allergic reactions or any known hypersensitivity or prior
reaction to any of the formulation excipients in the study drugs.

3. Known infection with HIV, HBV or HCV.

4. Anticipated use of chemotherapy or radiotherapy not specified in the study protocol
while on study

5. Any underlying medical condition that, in the Investigator's opinion, will make the
administration of study vector hazardous to the patient, would obscure the
interpretation of adverse events, or not permit adequate surgical resection.

6. Systemic treatment on any investigational clinical trial within 28 days prior to
registration.

7. Concurrent treatment with immunosuppressive or immunomodulatory agents, including any
systemic steroid (exception: inhaled or topically applied steroids, and acute and
chronic standard dose NSAIDs, are permitted). Use of a short course (i.e., ≤ 1 day) of
a glucocorticoid is acceptable to prevent a reaction to the IV contrast used for CT
scans.

8. Immunosuppressive therapy, including: cyclosporine, antithymocyte globulin, or
tacrolimus within 3 months of study entry.

9. History of prior experimental cancer vaccine treatment (e.g., dendritic cell therapy,
heat shock vaccine) within the last year

10. History of stage III or greater cancer, excluding urothelial cancer. Basal or squamous
cell skin cancers must have been adequately treated and the subject must be
disease-free at the time of registration. Subjects with a history of stage I or II
cancer, must have been adequately treated and have been disease-free for ≥ 2 years at
the time of registration.

11. Progressive or persistent viral or bacterial infection

- All infections must be resolved and the patient must remain afebrile for seven
days without antibiotics prior to being placed on study

- Urinary tract infection, including particularly bladder infection, must be
resolved prior to being placed on study

12. Unwilling or unable to comply with the protocol or cooperate fully with the
investigator and site personnel
We found this trial at
17
sites
5801 South Ellis Avenue
Chicago, Illinois 60637
 773.702.1234
Principal Investigator: Gary Steinberg, MD
Phone: 773-702-3498
University of Chicago One of the world's premier academic and research institutions, the University of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: William Clark, MD
Phone: 907-276-1455
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Cincinnati, Ohio 45212
Principal Investigator: Igor Dumbadze, M.D.
Phone: 513-841-7550
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Edison, New Jersey 08837
Principal Investigator: Benjamin Fand, MD
Phone: 732-494-9400
?
mi
from
Edison, NJ
Click here to add this to my saved trials
Gainesville, Florida 32610
Principal Investigator: Paul Crispen, MD
Phone: 352-265-0680
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
Los Angeles, California 90095
Principal Investigator: Karmin Chamie, MD
Phone: 310-794-3421
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
8701 W Watertown Plank Rd
Milwaukee, Wisconsin
(414) 955-8296
Medical College of Wisconsin The Medical College (MCW) of Wisconsin is a major national research...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Nashville, Tennessee 37232
Principal Investigator: Daniel Barocas, MD
Phone: 615-343-2120
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Omaha, Nebraska 68114
Principal Investigator: Andrew Trainer, MD
Phone: 402-669-9428
?
mi
from
Omaha, NE
Click here to add this to my saved trials
17607 Gold Plaza
Omaha, Nebraska 68130
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Orange, California 92868
Principal Investigator: Edward Uchio, MD
Phone: 714-456-8148
?
mi
from
Orange, CA
Click here to add this to my saved trials
Phoenix, Arizona 85032
Principal Investigator: Donald Lamm, M.D.
Phone: 602-493-6626
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
243 N Rd
Poughkeepsie, New York 12601
(845) 471-9410
Principal Investigator: Evan Goldfischer, MD
Phone: 845-437-5002
Premier Medical Group of the Hudson Valley Premier Medical Group offers comprehensive, integrated care providing...
?
mi
from
Poughkeepsie, NY
Click here to add this to my saved trials
San Diego, California 92093
?
mi
from
San Diego, CA
Click here to add this to my saved trials
Troy, Michigan 48084
Principal Investigator: Juan R Frontera, MD
Phone: 248-786-0467
?
mi
from
Troy, MI
Click here to add this to my saved trials
Tucson, Arizona 85715
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
Winston-Salem, North Carolina 26157
Principal Investigator: Ron Davis, MD
Phone: 336-716-1352
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials